Pharmaceutical News

RSS

Despite warning dangerous ADHD drug still being sold

According to the U.S. Food and Drug Administration, liver problems linked to the attention deficit drug Cylert and other generic versions of the drug make it too dangerous for the U.S. market.

25 Oct 2005

Taiwan to produce its' own version of Tamiflu

Taiwan has apparently responded to bird flu fears by starting work on its own version of the anti-viral drug, Tamiflu, without waiting for the manufacturer's consent.

23 Oct 2005

Importance of the drug Fuzeon (enfuvirtide) in the management of HIV

New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients.

20 Oct 2005

Separate guidelines needed for the treatment of organophosphorus insecticide self-poisoning

Organophosphorus insecticide poisoning is a major global health problem, with hundreds of thousands of deaths each year. Most of these are in developing countries but this type of poisoning is also an important type of self-poisoning in the developed countries.

20 Oct 2005

New drug safety officer for FDA will have more clout

The U.S. Food and Drug Administration has a new director to its Office of Drug Safety.

19 Oct 2005

Patents no problem say Roche when it comes to speeding up production of Tamiflu

High profile Swiss drug maker Roche says it will not let patents stand in the way of getting its Tamiflu drug to patients in the event of a bird flu pandemic.

19 Oct 2005

Court victory means breast cancer drug Herceptin will be available to more women

The court victory of British woman Barbara Clark to be treated with the breast cancer drug Herceptin, means that now more than 100 breast cancer patients in Cornwall and Devon could soon be prescribed the drug.

19 Oct 2005

Expert evaluates orlistat (Xenical)

A 60 mg low-dose version of the prescription weight-loss medication orlistat (marketed by GlaxoSmithKline as Xenical 120 mg) was found to be safe, effective and tolerable in overweight individuals, according to new data presented today at the 2005 Annual Meeting of NAASO, The Obesity Society in Vancouver, British Columbia.

18 Oct 2005

Bayer to produce new Tuberculosis drug at low prices for poor nations

A promising new antibiotic, moxifloxacin, produced by Bayer Healthcare is about to be tested against tuberculosis, a disease that kills 5,000 people a day.

18 Oct 2005

Drug company warns of risk of liver problems with antidepressant

The warning about possible liver-related problems with the depression drug, Cymbalta, has been expanded and doctors are being cautioned against its use in chronic liver disease patients.

18 Oct 2005

Ebixa (memantine) approved for the treatment of moderate Alzheimer's disease

The Committee for Medicinal Products for Human Use (CHMP) has announced its decision to extend Ebixa’s current indication (moderately severe to severe disease) to include moderate stages of Alzheimer’s disease (AD).

16 Oct 2005

Remicade can improve psoriasis symptoms

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

From The University of Manchester 13 Oct 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

100% efficacy for cervical cancer vaccine

Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 per cent effective.

10 Oct 2005

Artemisinin combination therapies have potential to be one of the major public health interventions for Africa in this decade

Despite changes in policy in many African countries, most cases of malaria are still treated with old drugs that often fail, say researchers the British Medical Journal.

3 Oct 2005

Governments considering reclassifying some drugs from prescription to over-the-counter status

Governments in several countries with public Pharmacare and in a few provinces in Canada are considering reclassifying some drugs from prescription to over-the-counter status. In a Canadian Medical Association Journal essay, Lynd and colleagues comment on the economic effects of such changes.

27 Sep 2005

Increlex - first major innovation in 20 years for the treatment of growth failure

Rush University Medical Center is participating in a clinical trial to evaluate the potential benefit of the first major innovation in 20 years for the treatment of growth failure.

26 Sep 2005

CytRx granted "Fast Track" designation for ALS drug

CytRx Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted "Fast Track" designation for the company's leading drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

26 Sep 2005

Potential oral drug for rheumatoid arthritis

A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.

26 Sep 2005

Important new lessons learned from aspirin

No other medicine is as common, inexpensive, and yet powerful in so many ways as aspirin; yet despite a century of experience with the drug, researchers are still learning important new lessons, while raising new questions, according to seven special articles in the Sept. 20, 2005, issue of the Journal of the American College of Cardiology.

20 Sep 2005